Screener / SEC EDGAR /CIK 0001048477 /10-K filed Feb 26, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Biomarin Pharmaceutical Inc BMRN

Compare with peers Embed
Planned sales, announced before they happen

0 trading plans running, 5 Form 144 notices for $4.3M

10-Q, 10-K and Form 144

What BMRN's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Apr 13, 2023 to Nov 16, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
G. Eric Davis
Executive Vice President, Chief Legal Officer and Secretary
Adopted 10b5-1 plan Mar 13, 2025 10-Q May 2, 2025
What the company wrote
During the three months ended March 31, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities as set forth in the table below. Type of Trading Arrangement Name Position Action Adoption/Termination Date Rule 10b5-1 (1) Non- Rule 10b5-1 (2) Total Shares of Common Stock to be Sold (3) Expiration Date G. Eric Davis Executive Vice President, Chief Legal Officer and Secretary Adoption March 13, 2025 X up to 28,107 November 3, 2025 (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan.
Erin Burkhart
Group Vice President and Chief Accounting Officer
Adopted 10b5-1 plan Nov 26, 2024 10-K Feb 24, 2025
What the company wrote
During the three months ended December 31, 2024, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities set forth in the table below. Type of Trading Arrangement Name Position Action Adoption/Termination Date Rule 10b5-1 (1) Non- Rule 10b5-1 (2) Total Shares of Common Stock to be Sold (3) Expiration Date Erin Burkhart Group Vice President and Chief Accounting Officer Adoption November 26, 2024 X up to 6,246 May 30, 2025 (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan.
Brian R. Mueller
Executive Vice President and Chief Financial Officer
Adopted 10b5-1 plan Sep 13, 2024 10-Q Oct 31, 2024
Cristin M. Hubbard
Executive Vice President and Chief Commercial Officer
Adopted 10b5-1 plan Sep 13, 2024 10-Q Oct 31, 2024
V. Bryan Lawlis
Director
Adopted 10b5-1 plan Feb 28, 2024 10-Q Apr 26, 2024
What the company wrote
During the three months ended March 31, 2024, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities set forth in the table below. Type of Trading Arrangement Name Position Action Adoption/Termination Date Rule 10b5-1 (1) Non- Rule 10b5-1 (2) Total Shares of Common Stock to be Sold (3) Expiration Date V. Bryan Lawlis Director Adoption February 28, 2024 X up to 6,600 August 30, 2024 (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan.
Erin Burkhart
Group Vice President and Chief Accounting Officer
Ended 10b5-1 plan Nov 29, 2023 10-K Feb 26, 2024
What the company wrote
During the three months ended December 31, 2023, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities set forth in the table below. Type of Trading Arrangement Name Position Action Adoption/Termination Date Rule 10b5-1 (1) Non- Rule 10b5-1 (2) Total Shares of Common Stock to be Sold (3) Expiration Date Erin Burkhart Group Vice President and Chief Accounting Officer Termination November 29, 2023 X up to 2,782 March 8, 2024 Erin Burkhart Group Vice President and Chief Accounting Officer Adoption November 29, 2023 X up to 5,709 November 29, 2024 (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan.
G. Eric Davis
Executive Vice President, Chief Legal Officer and Secretary
Adopted 10b5-1 plan Sep 13, 2023 10-Q Nov 2, 2023
Brian R. Mueller
Executive Vice President and Chief Financial Officer
Adopted 10b5-1 plan Aug 23, 2023 10-Q Nov 2, 2023
Henry J. Fuchs, M.D.
President of Worldwide Research & Development
Adopted 10b5-1 plan Aug 17, 2023 10-Q Nov 2, 2023
Jean-Jacques Bienaimé
Chairman and Chief Executive Officer
Adopted 10b5-1 plan Aug 7, 2023 10-Q Nov 2, 2023
Jeff Ajer
Executive Vice President, Chief Commercial Officer
Adopted 10b5-1 plan Apr 13, 2023 10-Q Aug 2, 2023
What the company wrote
During the three months ended June 30, 2023, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities set forth in the table below. Type of Trading Arrangement Name Position Action Adoption/Termination Date Rule 10b5-1* Non- Rule 10b5-1** Total Shares of Common Stock to be Sold*** Expiration Date Jeff Ajer Executive Vice President, Chief Commercial Officer Adoption April 13, 2023 X up to 77,259 July 12, 2024 * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. *** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan.
Show the other 3 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since Apr 28, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Sep 2, 2026 Davis George Eric
Officer
17,557 $1.2M
May 7, 2026 Friberg Gregory R
Officer
3,281 $177K
Mar 11, 2026 Guyer Charles Greg
Officer
16,486 $997K
Feb 26, 2026 Friberg Gregory R
Officer
6,326 $382K
Feb 26, 2026 Davis George Eric
Officer
26,061 $1.6M

From the Form 144 XML filed with the SEC, since Feb 26, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BMRN/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.